0000899243-20-007821.txt : 20200310 0000899243-20-007821.hdr.sgml : 20200310 20200310211508 ACCESSION NUMBER: 0000899243-20-007821 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200302 FILED AS OF DATE: 20200310 DATE AS OF CHANGE: 20200310 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Chirag K. CENTRAL INDEX KEY: 0001738701 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 20703732 MAIL ADDRESS: STREET 1: C/O AMNEAL PHARMACEUTICALS LLC STREET 2: 400 CROSSING BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-02 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001738701 Patel Chirag K. C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD, 3RD FLOOR BRIDGEWATER NJ 08807 1 1 1 0 President, Co-CEO & Director Class A Common Stock 2020-03-02 4 P 0 34641 3.87 A 40748 D Class A Common Stock 2020-03-03 4 P 0 156421 3.88 A 197169 D Class A Common Stock 2020-03-04 4 P 0 58938 3.97 A 256107 D The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.805 to $3.92, inclusive. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.75 to $4.00, inclusive. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.87 to $4.00, inclusive. The reporting person undertakes to provide, upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, full information regarding the number of shares transacted at each price, with respect to all transactions reported on this Form 4. /s/ Meredith Cook, Attorney-in-Fact 2020-03-10